Robotic technology available at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is enabling physicians to obtain tissue biopsies in previously hard-to-reach areas of the lung to test for cancer.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
